APA (7th ed.) Citation

Zhai, T., Mitamura, T., Wang, L., Kubota, S. I., Murakami, M., Tanaka, S., & Watari, H. (2023). Combination therapy with bevacizumab and a CCR2 inhibitor for human ovarian cancer: An in vivo validation study. Cancer Medicine, 12(8), 9697. https://doi.org/10.1002/cam4.5674

Chicago Style (17th ed.) Citation

Zhai, Tianyue, Takashi Mitamura, Lei Wang, Shimpei I. Kubota, Masaaki Murakami, Shinya Tanaka, and Hidemichi Watari. "Combination Therapy with Bevacizumab and a CCR2 Inhibitor for Human Ovarian Cancer: An in Vivo Validation Study." Cancer Medicine 12, no. 8 (2023): 9697. https://doi.org/10.1002/cam4.5674.

MLA (9th ed.) Citation

Zhai, Tianyue, et al. "Combination Therapy with Bevacizumab and a CCR2 Inhibitor for Human Ovarian Cancer: An in Vivo Validation Study." Cancer Medicine, vol. 12, no. 8, 2023, p. 9697, https://doi.org/10.1002/cam4.5674.